Jonathan Biller Sells 1,925 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Jonathan Biller sold 1,925 shares of the firm’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total transaction of $886,327.75. Following the sale, the executive vice president owned 20,819 shares of the company’s stock, valued at $9,585,692.17. This trade represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX traded up $3.78 during midday trading on Thursday, reaching $465.02. The company’s stock had a trading volume of 1,816,913 shares, compared to its average volume of 1,542,259. The company has a market cap of $117.98 billion, a P/E ratio of 32.79 and a beta of 0.30. The business’s 50 day moving average price is $459.11 and its two-hundred day moving average price is $427.29. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $362.50 and a fifty-two week high of $519.68.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 23.51% and a net margin of 31.35%. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Stifel Nicolaus reduced their price objective on shares of Vertex Pharmaceuticals from $455.00 to $445.00 and set a “hold” rating for the company in a research report on Tuesday, November 4th. Sanford C. Bernstein upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 12th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, February 4th. UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $535.00 to $545.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Finally, Barclays raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $414.00 to $606.00 in a research report on Tuesday, January 27th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $522.68.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue and outlook: Vertex reported solid Q4 revenue (~$3.19B) with management forecasting 2026 revenue roughly in line with street expectations and reiterating growth from its cystic fibrosis portfolio and newer medicines — a near-term reassurance for revenue trajectory. Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments
• Positive Sentiment: Pipeline expansion: Vertex announced a partnership with WuXi to broaden its autoimmune program beyond cystic fibrosis — a strategic move that supports longer-term growth expectations and analyst bullishness on pipeline upside. Vertex Partners With WuXi To Broaden Autoimmune Pipeline Beyond Cystic Fibrosis
• Neutral Sentiment: Guidance roughly in line: The company updated FY‑2026 revenue guidance to about $13.0–13.1B (in line with consensus); EPS guidance details were limited in the release, leaving investors focused on execution rather than a big surprise. Vertex Q4 press release / slides
• Neutral Sentiment: Analyst momentum/valuation coverage: Multiple analysts maintain bullish price targets (median target near $545), and commentary that VRTX is a long‑term momentum/valuation story likely helped sentiment despite mixed line‑items. Why Vertex is a Top Momentum Stock for the Long-Term
• Negative Sentiment: Small EPS miss and mixed beat: Reported EPS was $5.03 (slightly below consensus ~$5.05–5.07) — a modest disappointment even as revenue was essentially in-line/solid; some outlets noted the stock dipped on the headline EPS number. Vertex Q4 Earnings Miss Estimates (Zacks)
• Negative Sentiment: Insider selling: Several senior executives (multiple EVPs and the CAO) sold shares around Feb. 11 — a visible round of insider selling that can concern some investors even if sales may be routine or for diversification. QuiverQuant summary including insider trades

Institutional Trading of Vertex Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Access Investment Management LLC purchased a new stake in Vertex Pharmaceuticals during the second quarter valued at about $27,000. Swiss RE Ltd. bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $28,000. Chesapeake Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock valued at $25,000 after buying an additional 33 shares in the last quarter. Eagle Bay Advisors LLC bought a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $29,000. Finally, Legacy Investment Solutions LLC purchased a new stake in Vertex Pharmaceuticals in the second quarter worth approximately $29,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.